Associated Genetic Biomarkers
Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17) is a gene that encodes a protein that functions in B cell development and autoimmune response. The protein also functions in NF-kappaB and MAPK8/JNK activation. Missense mutations, silent mutations, frameshift insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
TNFRSF17 is altered in 0.50% of all cancers with colorectal adenocarcinoma, colon adenocarcinoma, glioblastoma, lung adenocarcinoma, and melanoma having the greatest prevalence of alterations .
The most common alterations in TNFRSF17 are TNFRSF17 A54T (0.08%), TNFRSF17 C21S (0.08%), TNFRSF17 E151K (0.08%), TNFRSF17 N91S (0.08%), and TNFRSF17 P145S (0.08%) .
TNFRSF17 status serves as an inclusion eligibility criteria in 9 clinical trials, of which 8 are open and 1 is closed. Of the trials that contain TNFRSF17 status as an inclusion criterion, 2 are early phase 1 (2 open), 6 are phase 1 (5 open), and 1 is phase 1/phase 2 (1 open).
Trials with TNFRSF17 status in the inclusion eligibility criteria most commonly target multiple myeloma and B-cell neoplasm .
The most frequent alterations to serve as inclusion eligibility criteria are TNFRSF17 Expression and TNFRSF17 Overexpression .
Idecabtagene vicleucel, cyclophosphamide, fludarabine, gc012f, and autologous anti-bcma-car-expressing cd4+/cd8+ t-lymphocytes fcarh143 are the most frequent therapies in trials with TNFRSF17 as an inclusion criteria .
Significance of TNFRSF17 in Diseases
Multiple Myeloma +
TNFRSF17 is an inclusion criterion in 8 clinical trials for multiple myeloma, of which 7 are open and 1 is closed. Of the trials that contain TNFRSF17 status and multiple myeloma as inclusion criteria, 2 are early phase 1 (2 open) and 6 are phase 1 (5 open) .
B-Cell Neoplasm +
TNFRSF17 is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF17 status and B-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.